未登录

K

Kelsey E. Huntington

brown university

H指数:14

被引数:706

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Identification of potential immune biomarkers for GSK-3 inhibitor elraglusib (9-ING-41) in patients with relapsed/refractory metastatic cancer

CANCER RESEARCH

IF16.6

2024-03-220

PRE

Modulation of the MSS and MSI colorectal cancer immune microenvironment with FOLFOX and FOLFIRI -/+ anti-PD-1 immunotherapy

CANCER RESEARCH

IF16.6

2024-03-220

PRE

Imipridones and EZH2 inhibitors induce similar changes in cytokines and regulated genes in GBM and DMG while vorinostat potentiates anti-tumor efficacy despite variability in cytokine profiles

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Heterogeneity of cytokine secretion in single senescent fibroblasts is impacted by ONC201 and ABT-263

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Molecular analysis of small cell lung cancer provides insights into mechanism of action underlying the novel drug combination of lurbinectedin and TIC10/ONC201

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Integrin inhibitor GLPG-0187 promotes T-cell killing of mismatch repair-deficient colorectal cancer cells by suppression of SMAD/TGF-β signaling

CANCER RESEARCH

IF16.6

2023-04-040

PRE

p21 (WAF1/CIP1) drives a secretory phenotype in senescent fibroblasts and promotes bystander cancer cell growth in the tumor microenvironment

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Synergistic combination therapy with ONC201/TIC10, Enzalutamide and Darolutamide in castration-resistant prostate cancer

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Bypassing immune evasion in colorectal cancer by integrin inhibition-mediated downregulation of PD-L1

CANCER RESEARCH

IF16.6

2023-04-040

PRE

TIC10/ONC201 in combination with ceralasertib exhibits potent synergy in high grade serous ovarian cancer cells

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Inclusive basic and advanced translational laboratory research competencies for research in cancer biology and therapeutics

CANCER RESEARCH

IF16.6

2023-04-040

PRE

El-Deiry, Wafik S.; George, Andrew; Di Cristofano, Francesca; Srinivasan, Praveen; Carlsen, Lindsey; Huntington, Kelsey E.; De La Cruz, Arielle; Zhang, Leiqing; Hahn, Marina; Zhao, Shuai; Seyhan, Attila; DeNardo, Bradley D.; Maxwell, Aaron W.; Kim, Dae Hee; Raufi, Alex; Khan, Hina; Graff, Stephanie L.; Dizon, Don S.; Azzoli, Christopher; Abbas, Abbas E.; Wood, Roxanne; Lulla, Rishi R.; Safran, Howard P.; Carneiro, Benedito A.; Navaraj, Arunasalam; Tian, Xiaobing; Zhang, Shengliang; Zhou, Lanlan

PARP inhibitor rucaparib in combination with imipridones ONC201 or ONC212 demonstrates preclinical synergy against BRCA1/2-deficient breast, ovarian, and prostate cancer cells

PARP抑制剂rucaparib与imipridones ONC201或ONC212的组合显示出对BRCA1/2缺陷的乳腺癌，卵巢癌和前列腺癌细胞的临床前协同作用

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Androgen signaling blockade enhances NK cell-mediated killing of prostate cancer cells (PC) and promotes NK cell tumor infiltration in vivo

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Multiplex digital spatial profiling (DSP) of proteins in the tumor microenvironment in response to GSK-3 inhibition by 9-ING-41 (elraglusib) correlates with novel immunostimulatory effects observed in vivo

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Classical chemotherapy modulates cytokine secretion in the MSS CRC immune microenvironment and enhances T cell killing

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Combination of 5-Fluorouracil or ONC212 plus KRAS G12D inhibitor MRTX1133 against colorectal and pancreatic cancer cells results in immune-stimulatory cytokine patterns and unexpected synergies independent of G12D mutation

CANCER RESEARCH

IF16.6

2023-04-041

PRE

Normal fibroblasts, cancer-associated fibroblasts, and their senescent counterparts exert varying effects on tumorigenic potential and ABT-263 sensitivity of gastric cancer cells

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Combination treatment with pH modulating drugs and immune checkpoint inhibitors increases TALL-104 cytotoxicity in preclinical co-culture experiments

CANCER RESEARCH

IF16.6

2023-04-040

PRE

The immunostimulatory effect of 9-ING-41, a small molecule GSK-3 inhibitor, in sarcomas

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Co-culture of circulating tumor cells (CTCs)-derived 3D organoids and autologous cytotoxic CD8+T cells: A new functional precision oncology platform

CANCER RESEARCH

IF16.6

2023-04-040

PRE